Life Stem Genetics Strengthens Its Executive Advisory Board by Adding MBAs Matthew Sullivan and Shahab Bakhtyar

LOS ANGELES--(BUSINESS WIRE)--

Life Stem Genetics Inc., an emerging innovator in the advancement of Adult Stem Cell therapy, is pleased to announce that Matthew Sullivan, COO of global heath products company Asana International, and Shahab Bakhtyar, an independent medical business consultant with global experience, have joined Life Stems Executive Advisory Board.

Established earlier this year, the Executive Advisory Board has become a cornerstone of Life Stems global stem-cell growth model by actively retaining influential business leaders with broad backgrounds in corporate development and finance in our targeted industries with a focus on business expansion into Canada, Europe, Asia, and the Middle East.

Matthew Sullivan, BA, MBA, is a corporate finance specialist who has worked with numerous early-stage and well-established companies in operations as well as strategic and financial planning. Matthews background is in venture capital and business analysis. His role has ranged from business planning/implementation, M&A, market analysis to operational implementation. He is currently COO of Asana International, a global health products company, CFO of Kat Gold Holdings, a publicly traded gold production and exploration company based in Ghana, and CFO of Travelvu, a business that places smart devices in hotel rooms. Matthew holds a Bachelor of Arts degree from the University of British Columbia, Canada, and an MBA from Dalhousie University, Canada.

Shahab Bakhtyar, MBA, is an independent business consultant with a focus on expansion and financing of small to medium sized businesses. In the last 15 years, Mr. Bakhtyars consultancy has focused mainly on Western Canada where he includes medical/health service providers among his clientele. Prior to establishing his business in Canada, Mr. Bakhtyar worked in Dubai, UAE. Included among his clients were Emirate Air and FIFA to whom he provided marketing and advertising services. Mr. Bakhtyar holds an MBA from Queens University, Canada. He has traveled to over 63 countries and maintains a strong international network of business contacts with a focus throughout the Middle East and Canada.

The addition of Matthew and Shahab to our advisory board aligns with our goal of developing a team of advisors who share our core values and can help us attain our growth initiatives in the rapidly advancing Adult Stem Cell therapy business sector, says Gloria Simov, president and CEO of Life Stem Genetics. Life Stem will greatly benefit from the depth of industry expertise and overall business acumen that both Matthew and Shahab bring, and we look forward to their value-added contributions as we continue to build our base of stem cell clinics throughout the world.

About Life Stem Genetics

Life Stem Genetics (LSG) is a progressive healthcare company focused on Adult Stem Cell (ASC) healing therapies. For decades, stem cells have been utilized in the successful treatment of a variety of ailments. Today, advanced ASC therapies are being offered to patients as an efficient and painless alternative treatment for a wide range of ailments including, but not limited to, orthopedic injuries, neurological disorders such as Parkinsons and Alzheimers, cancer, arthritis, diabetes, multiple sclerosis, as well as age management. Adult Stem Cell therapies and LSGs proprietary techniques are experiencing some of the best results in the industry in helping to repair or reprogram damaged or diseased tissues and organs. Life Stems ASC specialist has performed thousands of stem cell treatments including some of the top names in PGA golf, NFL football, NBA basketball, and Major League Baseball. LSG will offer its proprietary treatments through a series of affiliate doctors and medical clinics with 60 affiliated clinics thus far. LSGs mission is to develop a comprehensive approach to the treatment and maintenance of diseases while breaking free from the medical insurance maze by tapping into an affordable private-pay sector.

Contrarian Press, the publisher, has been engaged by Life Stem Genetics to assist with identification of potential market participants who may be interested in learning more about the company and its securities. Updated disclaimer and disclosure information is available at the publisher's website listed above and at the following link:

http://www.contrarianwealthcoalition.com/guide/LIFS.pdf

More here:
Life Stem Genetics Strengthens Its Executive Advisory Board by Adding MBAs Matthew Sullivan and Shahab Bakhtyar

'Radical' stem cell trial offers hope for MS sufferers

Oct. 27, 2013, 3 a.m.

Jason McIntyre's autoimmune system is dead. The rest of him isn't feeling much better. Eleven days ago he underwent an aggressive chemotherapy, not for the sake of killing cancer - but to knock out every skerrick of protection his body has against infection.

Sitting in a freezer were 35 million stem cells that were shaken from Mr McIntyre's bone marrow by a combination of drugs. These were filtered from his blood about three weeks ago. That process, he says, left him with aching bones. It was his birthday.

If he survives long enough - that is, if a piece of dust doesn't get in his eye and spark a fatal infection - the stem cells will this week be returned to his body, as building blocks for a brand new autoimmune system.

Mr McIntyre, 37, is only the sixth patient with multiple sclerosis to undergo this experimental therapy - known as an autologous haematopoietic stem cell transplant - in a small trial being conducted by St Vincent's Hospital in Sydney.

Thousands of stem cell transplants are performed worldwide to treat certain blood cancers in patients who have become resistant to regular therapies - but the numbers of MS sufferers treated with a stem cell transplant are in the hundreds.

It's a strategy reserved for people like Jason McIntyre whose form of MS is very aggressive and resistant to drug therapy.

About three years ago, the Melbourne truck driver arrived home with blurry vision. He told his wife, Kym, that he couldn't read the number plates on cars. Soon after, following a session at the gym, he was ''boiling hot and his vision went blurry again''.

Kym McIntyre says it all happened pretty quickly. He started dragging his left foot. He couldn't unscrew bottle tops and lost his co-ordination.

An eye doctor recognised the problem as multiple sclerosis, but Mr McIntyre was told by a specialist that he'd have to wait for another attack - another lesion on the brain to develop - for the diagnosis to be confirmed.

See the original post:
'Radical' stem cell trial offers hope for MS sufferers

Stem cell technology put to work in search for hair treatments

Acure for baldness doesn't leap to mind when one ponders the next advance in stem cell research, but whoever manages to do it stands to become very rich.

Scientists around the world have already grown liver and brain cells in the laboratory using cell samples from humans. Others - including some working for a Vancouver-based company - are hard at work trying to find a way to nurture new hair growth on shiny heads.

"It's a market where people spend a ton of money," says David Hall, CEO of RepliCel Life Sciences Inc., a biotech firm with offices in downtown Vancouver that has attracted the attention of Japan's Shiseido Co.

The cosmetic giant paid $4.2 million in July to share Repli-Cel's research on a highly speculative technology for treating hair loss.

Hall, who says his own flowing locks have no high-tech enhancement, acknowledges that plenty of people think hair-cloning research is frivolous. But those usually aren't people who are losing their hair, particularly at a young age.

"It's just not perceived as a medical need, but I think there are a lot of people who would say it's important to them," Hall says. "There's definitely a mental health aspect for young men and for women in their 30s and 40s. It can be very devastating to their self-esteem."

Hair transplants are still the "gold standard" for hair restoration, he says, but their success relies on the skill of the surgeon and a supply of healthy follicles from elsewhere on the scalp.

The RepliCel technique was pioneered by company cofounders Dr. Rolf Hoffmann, a German dermatologist, and Vancouver researcher Kevin McElwee. Hair follicles are harvested from the back of a person's scalp, where hair is typically resistant to the hormone that causes baldness. That tissue is transferred to the lab, where researchers isolate dermal sheath cup cells from the base of the follicle. Those cells are replicated by the millions over a period of three months, later to be injected into bald areas at the top of the scalp using a specially designed device.

"What initially attracted me to this concept is it's not a drug," says Hall. "The treatment uses the patient's own cells to replace hormone-compromised hair follicle cells in the bald areas. The concept of treating cellular deficits with your own cells is elegant. It's the same concept we're using in our other treatment in development for chronic tendinosis."

The company hopes to have a clinical trial with 120 men test the procedure in Germany in coming months as it works its way through regulatory requirements that could ultimately lead to licensing in Europe, the U.S. and Japan. It has already completed an initial trial of 19 subjects that found no serious adverse reactions six months after injections.

More here:
Stem cell technology put to work in search for hair treatments

Lou Gehrig’s disease: From patient stem cells to potential treatment strategy

Oct. 25, 2013 Although the technology has existed for just a few years, scientists increasingly use "disease in a dish" models to study genetic, molecular and cellular defects. But a team of doctors and scientists led by researchers at the Cedars-Sinai Regenerative Medicine Institute went further in a study of Lou Gehrig's disease, a fatal disorder that attacks muscle-controlling nerve cells in the brain and spinal cord.

After using an innovative stem cell technique to create neurons in a lab dish from skin scrapings of patients who have the disorder, the researchers inserted molecules made of small stretches of genetic material, blocking the damaging effects of a defective gene and, in the process, providing "proof of concept" for a new therapeutic strategy -- an important step in moving research findings into clinical trials.

The study, published Oct. 23 in Science Translational Medicine, is believed to be one of the first in which a specific form of Lou Gehrig's disease, or amyotrophic lateral sclerosis, was replicated in a dish, analyzed and "treated," suggesting a potential future therapy all in a single study.

"In a sense, this represents the full spectrum of what we are trying to accomplish with patient-based stem cell modeling. It gives researchers the opportunity to conduct extensive studies of a disease's genetic and molecular makeup and develop potential treatments in the laboratory before translating them into patient trials," said Robert H. Baloh, MD, PhD, director of Cedars-Sinai's Neuromuscular Division in the Department of Neurology and director of the multidisciplinary ALS Program. He is the lead researcher and the article's senior author.

Laboratory models of diseases have been made possible by a recently invented process using induced pluripotent stem cells -- cells derived from a patient's own skin samples and "sent back in time" through genetic manipulation to an embryonic state. From there, they can be made into any cell of the human body.

The cells used in the study were produced by the Induced Pluripotent Stem Cell Core Facility of Cedars-Sinai's Regenerative Medicine Institute. Dhruv Sareen, PhD, director of the iPSC facility and a faculty research scientist with the Department of Biomedical Sciences, is the article's first author and one of several institute researchers who participated in the study.

"In these studies, we turned skin cells of patients who have ALS into motor neurons that retained the genetic defects of the disease," Baloh said. "We focused on a gene, C9ORF72, that two years ago was found to be the most common cause of familial ALS and frontotemporal lobar degeneration, and even causes some cases of Alzheimer's and Parkinson's disease. What we needed to know, however, was how the defect triggered the disease so we could find a way to treat it."

Frontotemporal lobar degeneration is a brain disorder that typically leads to dementia and sometimes occurs in tandem with ALS.

The researchers found that the genetic defect of C9ORF72 may cause disease because it changes the structure of RNA coming from the gene, creating an abnormal buildup of a repeated set of nucleotides, the basic components of RNA.

"We think this buildup of thousands of copies of the repeated sequence GGGGCC in the nucleus of patients' cells may become "toxic" by altering the normal behavior of other genes in motor neurons," Baloh said. "Because our studies supported the toxic RNA mechanism theory, we used two small segments of genetic material called antisense oligonucleotides -- ASOs -- to block the buildup and degrade the toxic RNA. One ASO knocked down overall C9ORF72 levels. The other knocked down the toxic RNA coming from the gene without suppressing overall gene expression levels. The absence of such potentially toxic RNA, and no evidence of detrimental effect on the motor neurons, provides a strong basis for using this strategy to treat patients suffering from these diseases."

View original post here:
Lou Gehrig’s disease: From patient stem cells to potential treatment strategy

Stem-cell therapy not advised for Parkinson's

From $1,305 Per Month

2 Bedrooms 1.5 Baths

via Apartments.com

(248) 556-3772

Roommate pricing from $550 each!village park of royal oak apartments in royal oak, mi offers spacious one-, two- and three-bedroom apartments for rent with energy-saving windows, updated kitchens and baths and whirlpool appliances including above the range microwaves.royal oak, michigan is a trendy, exciting and fun place to live and so is village park of royal oak apartments, with two convenient locations - one downtown and one near i-696 and i-75. apartment community amenities include a resort-class clubhouse, fitness center and pool with sun deck. our residents tell us they live at village park of royal oak apartments in royal oak, mi because: 1. two unique locations, one less than a mile from downtown royal oak and one less than a mile from i-75 2. resort-class swimming pool and hot tub 3. renovated kitchens including new cabinetry, upgraded whirlpool appliances, new countertops, energy-efficient lighting, above-the-range microwaves and wood vinyl flooring 4. 5,500 square foot multi-million dollar clubhouse with 24-hour fitness center, racquetball court, free wifi, business center and conference room 5. three spacious floor plans, 1, 2, and 3 bedroom apartment homes 6. walking distance to mark ridley's comedy castle, the royal oak music theater, royal oak farmer's market and much more 7. resident events led by on-site lifestyle director 8. 24-hour maintenance, snow removal and landscape care 9. pet-friendly 10. roommate rewards program which offers 50% off all your fees including security deposit with qualifying credit and roommate forgiveness recipient of the cel and associates a list award for customer service

See the original post here:
Stem-cell therapy not advised for Parkinson's

Stem Cell Transplants May Harm Recipient's Sex Life

THURSDAY, Oct. 24 (HealthDay News) -- Blood and bone marrow stem cell transplants may put a damper on the sex lives of cancer patients, a new study suggests.

This type of stem cell transplant is an increasingly effective form of treatment for patients with blood cancers such as leukemia, lymphoma and myeloma. Writing in the Oct. 24 issue of Blood, researchers say that while stem cell transplant was once tied to a high risk of death, survival rates have steadily risen and there's now more focus on the patients' quality of life, including their sexual well-being.

"It is not often that the transplant team and patient will have a conversation about how this procedure could impact their sex life, even after recovery," study lead author F. Lennie Wong, of City of Hope in Duarte, Calif., said in a journal news release. "However, we hope these findings will help encourage patients and their doctors to openly discuss concerns related to sexual dysfunction and address them with specialists who can help."

The new study included 152 men and 125 women averaging 48 years of age, who underwent stem cell transplants between 2001 and 2005, and were followed-up for three years.

The percentage of men who said they were sexually active fell from 61 percent before the procedure to 54 percent afterwards, but rose from 37 percent to 52 percent among women, according to the study.

Among men who received total body radiation, there was a nearly 18 percent decline in sexual function, a 32 percent decrease in sexual satisfaction, a 26 percent drop in both sexual behavior/experience and quality of orgasm, and a 17 percent decrease in sex drive/relationship. Radiation treatment did not appear to affect women in these areas, the study authors noted in the news release.

Men who developed stem cell transplant rejection -- where the body's immune system fights the new cells -- had a 21 percent decrease in sexual thoughts/fantasy and a 24 percent decline in the quality of orgasm, the findings showed. Women who experienced transplant rejection had a 27 percent decline in both sexual satisfaction and sexual arousal.

Overall, women experienced significantly worse sexual effects than men, despite the fact that their sexual activity increased after their transplant, the investigators concluded.

The researchers believe that nearly half of people who undergo stem cell transplant are sexually inactive three years after their transplant. Patients may benefit from speaking with their doctors about their sexual health, the authors suggested.

-- Robert Preidt

Here is the original post:
Stem Cell Transplants May Harm Recipient's Sex Life

Metro Detroit Boy A ‘Living Miracle’ After Stem Cell Treatment For Cerebral Palsy

SHELBY TWP. (WWJ) - Thanks to modern technology and medical breakthrough, a metro Detroit boy with cerebral palsy is experiencing a miracle.

We first met the Kijeks last Januaryand between smiles and laughter, we met Drew. Diagnosed with cerebral palsy shortly after birth,life with Drew hasnt been easy.

If he tried sitting and we let him go for even a split second, he would just tip over because he didnt have any balance, Drews mother Maureen Kijek told WWJs Kathryn Larson.

But now a new door has opened for the Shelby Township boy. Drew was one of the first children in the world to participate in a procedure to treat his cerebral palsy with the use of cord blood stem cells.

He would always get very frustrated, being trapped in a body that doesnt work. And so for me to see him smile and to see the look of contentment on his face and pride when he does something, however small that it might seem to other people, itshuge for him. You know, the fact that hes doing two things at once, hes sitting independently, hes able to use his hands where before he could only really do one little thing at a time, Kijek said.

The 12-year-olds physical therapist Kathleen Lewandowski said she almost cant believe her eyes.

For us, we were thrilled if he held his head up for five seconds, 10 seconds, 30 seconds, if he could track something consistently and for him to sit, I mean, its a miracle. Ive been a therapist for 10 years and that doesnt happen, Lewandowski said.

Kijek, who banked her sons stem cells at birth,saidits nothing short of a miracle.

Its incredible and its all those things that people think Oh, it could never happen, or its science fiction or whatever, but its not. Its just the bodys way of healing itself and getting back to the wholeness that it always wanted to be. And, you know, with the help of the stem cells, which replace the bad cells, Kijek said. I dont see any reason why the FDA wouldnt do this. Its safe, its effective, it works.

Shortly after we metDrew last year, the Kijeks flew to Georgia for the first of two FDA trial visits. Drew was fully awake for the procedure that involved intravenously injecting either his own stem cells or a placebo.

See the article here:
Metro Detroit Boy A ‘Living Miracle’ After Stem Cell Treatment For Cerebral Palsy

Stem cell therapy used in Sikeston in dogs

SIKESTON, MO (KFVS) -

Stem cell therapycan bea very controversial issue, but now some veterinarians are using new techniques to harvest those cells.

The cutting edge procedure helps fight degenerative diseases and has only been performed a few times in Missouri.

Experts say regenerative medicine using stem cells is a less invasive and more cost effective alternative for dogs suffering from osteoarthritis and cartilage injuries.

Googus is an 8 year old Boxer mix diagnosed with degenerative myelopathy.

This terminal disease affects the spinal cord causing loss of control in the hind legs.

"Even though they're unable to use their back legs they're still normal in their brain and they just don't understand why they can't walk," said Dr. Stephen Williams, Animal Health Center. "There's just not a good connection and transmission from the nerves to the back legs."

But new technology could slow, if not stop, its progression. Dr. Williams is using stem cell therapy to counteract this and other degenerative diseases in dogs.

"The stem cells from the patient are the ones that are going to benefit that same patient versus trying to take stem cells from a different dog and putting them in this dog," said Dr. Williams. "By harvesting the stem cells from the fat versus people have heard of stem cells from umbilical cords and stuff like that we're taking it from the fat tissue and harvesting those and actually activating with a fluorescent light."

Once the fat is extracted it's a two hour process to prepare the new stem cells. Those are then injected back into the patient along with platelets that work with the immune system to fight the disorder.

Read the rest here:
Stem cell therapy used in Sikeston in dogs